Why ivosidenib + azacitidine instead of monotherapy in 1L?

AGILE showed ivosidenib + azacitidine improved event-free survival, complete remission rate, and overall survival compared to azacitidine alone in newly diagnosed IDH1-mutant AML in patients ineligible for intensive chemotherapy. The combination is the new standard for that population.

What is the role of venetoclax-based therapy in IDH-mutant AML?

Venetoclax + azacitidine (VIALE-A) is an alternative low-intensity 1L for IDH-mutant AML, with strong response rates particularly in IDH2-mutant disease. The choice between venetoclax+aza and ivosidenib+aza in IDH1-mutant patients is an active area of clinical decision-making, weighing AE profile, prior treatment, and access.

Olutasidenib vs ivosidenib for R/R IDH1-mutant AML?

Both are FDA-approved for R/R IDH1-mutant AML. Olutasidenib showed a CR/CRh rate of ~35% in pivotal trials with manageable safety; ivosidenib has a longer track record. Cross-resistance is not complete — olutasidenib may have activity after ivosidenib in some cases — but data are limited.

Variant cheat sheet · acute myeloid leukemia

IDH1 and IDH2 in acute myeloid leukemia

Free clinical reference. Educational use only — not a substitute for professional medical advice.

TL;DR

IDH1 R132 and IDH2 R140 / R172 mutations in AML are AMP/ASCO/CAP Tier I-A. Ivosidenib (IDH1) and enasidenib (IDH2) target the mutant enzyme. Ivosidenib + azacitidine (AGILE) is 1L for IDH1-mutant AML in patients ineligible for intensive chemotherapy. Olutasidenib is a second-generation IDH1 inhibitor for relapsed/refractory disease. Differentiation syndrome is a class-effect adverse event that must be recognized and managed early.

Biology

IDH1 (cytoplasmic) and IDH2 (mitochondrial) are isocitrate dehydrogenases. Recurrent neomorphic mutations (R132 in IDH1, R140 or R172 in IDH2) cause the enzyme to produce the oncometabolite 2-hydroxyglutarate (2-HG), which inhibits alpha-ketoglutarate-dependent dioxygenases including the TET DNA demethylases. The resulting hypermethylation phenotype blocks myeloid differentiation. IDH inhibitors restore differentiation rather than directly killing leukemic blasts — which is why differentiation syndrome is the dose-limiting toxicity.

Epidemiology

IDH1 mutations occur in ~7-14% of AML, IDH2 in ~8-19%. More common in older patients and intermediate-risk cytogenetic categories. Often co-occur with NPM1, DNMT3A, FLT3-ITD.

Detection

NGS panel at AML diagnosis — captures IDH1/2 along with the full co-mutation profile.
Single-gene PCR also available for IDH1 R132 and IDH2 R140/R172.
Serum 2-HG measurement is feasible but mostly investigational.

FDA-approved targeted therapies

Drug	Indication	Line	Tier
Ivosidenib + azacitidine	Newly diagnosed IDH1-mutant AML, ineligible for intensive chemo (AGILE)	1L (low-intensity)	I-A
Ivosidenib monotherapy	R/R IDH1-mutant AML; newly diagnosed chemo-ineligible monotherapy	R/R or 1L low-intensity	I-A
Olutasidenib	R/R IDH1-mutant AML	R/R	I-A
Enasidenib	R/R IDH2-mutant AML	R/R	I-A

Tier = AMP/ASCO/CAP 2017 (Li MM et al., J Mol Diagn 2017). Drug names link to openFDA labels where available. Synthetic data; consult primary sources before treatment.

Resistance pathways

IDH isoform switching: emergence of IDH2 mutation on IDH1 inhibitor (or vice versa).
Second-site mutations in IDH (Q316E in IDH2).
Receptor tyrosine kinase activation (FLT3, KIT) bypassing IDH dependence.

Caveats

Differentiation syndrome (formerly IDH-DS, similar to APL differentiation syndrome) presents with fever, dyspnea, pulmonary infiltrates, hypotension, peripheral edema, hyperleukocytosis, renal dysfunction, and rash. Onset is usually within 90 days of IDH inhibitor initiation. Treatment is corticosteroids (dexamethasone) and supportive care; the IDH inhibitor can usually be continued. Early recognition is critical.

Frequently asked questions

Why ivosidenib + azacitidine instead of monotherapy in 1L?: AGILE showed ivosidenib + azacitidine improved event-free survival, complete remission rate, and overall survival compared to azacitidine alone in newly diagnosed IDH1-mutant AML in patients ineligible for intensive chemotherapy. The combination is the new standard for that population.
What is the role of venetoclax-based therapy in IDH-mutant AML?: Venetoclax + azacitidine (VIALE-A) is an alternative low-intensity 1L for IDH-mutant AML, with strong response rates particularly in IDH2-mutant disease. The choice between venetoclax+aza and ivosidenib+aza in IDH1-mutant patients is an active area of clinical decision-making, weighing AE profile, prior treatment, and access.
Olutasidenib vs ivosidenib for R/R IDH1-mutant AML?: Both are FDA-approved for R/R IDH1-mutant AML. Olutasidenib showed a CR/CRh rate of ~35% in pivotal trials with manageable safety; ivosidenib has a longer track record. Cross-resistance is not complete — olutasidenib may have activity after ivosidenib in some cases — but data are limited.